Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS)
- Previous Close
56.60 - Open
55.00 - Bid 57.43 x --
- Ask 57.45 x --
- Day's Range
54.01 - 57.74 - 52 Week Range
32.72 - 59.71 - Volume
3,989,728 - Avg. Volume
3,415,644 - Market Cap (intraday)
26.384B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-2.07 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.
www.dizalpharma.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 688192.SS
View MorePerformance Overview: 688192.SS
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688192.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688192.SS
View MoreValuation Measures
Market Cap
26.00B
Enterprise Value
26.10B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
59.74
Price/Book (mrq)
60.69
Enterprise Value/Revenue
66.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-237.73%
Return on Assets (ttm)
--
Return on Equity (ttm)
-133.26%
Revenue (ttm)
360.39M
Net Income Avi to Common (ttm)
-856.77M
Diluted EPS (ttm)
-2.07
Balance Sheet and Cash Flow
Total Cash (mrq)
808.3M
Total Debt/Equity (mrq)
206.74%
Levered Free Cash Flow (ttm)
--